Department of Radiology, Stanford University, Stanford, California;
Department of Dermatology, Stanford University, Stanford, California; and.
J Nucl Med. 2021 Oct;62(10):1380-1383. doi: 10.2967/jnumed.120.254482. Epub 2021 Feb 5.
Our purpose was to investigate the prognostic value of F-FDG PET/CT parameters in melanoma patients before beginning therapy with antibodies to the programmed cell death 1 receptor (anti-PD-1). Imaging parameters including SUV, metabolic tumor volume, and the ratio of bone marrow to liver SUV (BLR) were measured from baseline PET/CT in 92 patients before the start of anti-PD-1 therapy. The association with survival and imaging parameters combined with clinical factors was evaluated. Clinical and laboratory data were compared between the high-BLR group (>median) and the low-BLR group (≤median). Multivariate analyses demonstrated that BLR was an independent prognostic factor for progression-free and overall survival ( = 0.017 and = 0.011, respectively). The high-BLR group had higher white blood cell counts and neutrophil counts and a higher level of C-reactive protein than the low-BLR group ( < 0.05). Patients with a high BLR were associated with poor progression-free and overall survival, potentially explained by evidence of systemic inflammation known to be associated with immunosuppression.
我们的目的是研究氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）参数在开始接受程序性死亡受体 1 抗体（抗 PD-1）治疗前对黑色素瘤患者的预后价值。92 例患者在开始抗 PD-1 治疗前进行了基线 FDG PET/CT，测量了包括 SUV、代谢肿瘤体积和骨髓与肝脏 SUV 比值（BLR）在内的影像学参数。评估了与生存和影像学参数相结合的临床因素的相关性。对高 BLR 组（>中位数）和低 BLR 组（≤中位数）之间的临床和实验室数据进行了比较。多因素分析表明，BLR 是无进展生存期和总生存期的独立预后因素（=0.017 和=0.011）。高 BLR 组的白细胞计数和中性粒细胞计数以及 C 反应蛋白水平均高于低 BLR 组（<0.05）。高 BLR 患者的无进展生存期和总生存期较差，这可能与已知与免疫抑制相关的全身炎症证据有关。
